- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Sa | Fast on GlaxoSmithKline's heels, Aurinia wins OK to steer a second lupus nephritis drug straight to the market | ||
| Fr | Yale cancer specialist Charlie Fuchs tapped as new global development chief for Roche/Genentech | ||
| Fr | Neuvogen uncloaks with broad plan of attack for whole-cell cancer vaccines, clinical hopes within the year | ||
| Fr | News briefing: Eli Lilly completes $1B+ Prevail buyout; Elzonris approved in Europe for adults | ||
| Fr | Flush with cash to change the generics supply chain, Civica Rx looks to break ground on first in-house manufacturing site | ||
| Fr | Can a new CRISPR technique unlock the secrets of how cancer spreads? | ||
| Fr | Diem Nguyen tapped to lead 'point of inflection' at Xalud Therapeutics; Diana Escolar dances her way to Avrobio CMO | ||
| Fr | What does $29B buy you in Big Pharma? In GlaxoSmithKline's case, a whole lot of uncomfortable questions about the pipeline | ||
| Fr | Biden institutes regulatory freeze on first day of presidency | ||
| Fr | Incyte's PD-1 priority review draws muted applause - but analysts say it's all about getting a foot in the door | ||
| Fr | GlaxoSmithKline scraps a LAG3 study, marking another failure for the pipeline after a critical setback | ||
| Fr | Covid-19 roundup: Pfizer/BioNTech will reportedly supply vaccines to COVAX as Poland threatens lawsuit over shortfalls | ||
| Do | After stinging FDA setback, GlaxoSmithKline's ViiV finally notches US approval for long-acting HIV injection | ||
| Do | Months after a major rebranding around CAR-NKT cells, Kuur Therapeutics is offering a peek at early results | ||
| Do | Deval Patrick joins Cerevel board, further intertwining company with Bain Capital | ||
| Do | Northway Biotech sets up shop in Boston hub, looking to court more customers with biologics-focused plant | ||
| Do | News briefing: Five public biotechs, over 2 days, raise $883M from fresh offerings; Belgian biotech expands Series B funding | ||
| Do | Covid-19 roundup: Italy wonders aloud if it can sue Pfizer for vaccine shortfalls; US recommits to WHO under Biden administration | ||
| Do | Plexium adds industry vet Mike Grey to the brain trust with new investor cash funding its protein degradation play | ||
| Do | Eli Lilly's antibody cuts risk of Covid-19 by up to 80% among the most vulnerable - but will it have a place next to vaccines? | ||
| Do | Endpoints poll: Janet Woodcock takes the (interim) helm at the FDA. And a large majority of our readers want her to stay there | ||
| Do | With patent concerns looming, Roche gets a new priority review on blockbuster IPF drug | ||
| Do | BIO looks to restructure, laying off staff amid challenge to the trade org's normal face-to-face style | ||
| Do | What's next for Endpoints - and how to support our independent biopharma news mission | ||
| Do | FDA guides on Covid-19 considerations in cell and gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
